Abaxis Stock Price, News & Analysis (NASDAQ:ABAX)

$66.95 -1.53 (-2.23 %)
(As of 02/23/2018 09:42 AM ET)
Previous Close$68.48
Today's Range$66.35 - $68.71
52-Week Range$43.66 - $78.53
Volume108,000 shs
Average Volume267,767 shs
Market Capitalization$1.55 billion
P/E Ratio56.60
Dividend Yield0.93%
Beta1.26

About Abaxis (NASDAQ:ABAX)

Abaxis logoAbaxis, Inc. is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force. The Company's segments are the medical market and the veterinary market. The Company's medical market products include Piccolo chemistry analyzers and consumable products. The Company develops, manufactures and sells the Piccolo Xpress chemistry analyzer for use in human patient care to provide clinicians with blood constituent measurements. The Company's veterinary market product offerings include VetScan chemistry analyzers and veterinary reagent discs, VetScan hematology instruments and related reagent kits, VetScan VSpro specialty analyzers and related consumables, VetScan i-STAT analyzers and related consumables and VetScan rapid tests.

Receive ABAX News and Ratings via Email

Sign-up to receive the latest news and ratings for ABAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ABAX
CUSIP00256710
Phone510-675-6500

Debt

Debt-to-Equity RatioN/A
Current Ratio5.92%
Quick Ratio4.92%

Price-To-Earnings

Trailing P/E Ratio56.6
Forward P/E Ratio55.79
P/E Growth11.25

Sales & Book Value

Annual Sales$227.22 million
Price / Sales6.69
Cash Flow$1.60 per share
Price / Cash41.74
Book Value$12.38 per share
Price / Book5.41

Profitability

Trailing EPS$1.08
Net Income$32.71 million
Net Margins10.51%
Return on Equity10.09%
Return on Assets8.69%

Miscellaneous

Employees584
Outstanding Shares22,700,000

Abaxis (NASDAQ:ABAX) Frequently Asked Questions

What is Abaxis' stock symbol?

Abaxis trades on the NASDAQ under the ticker symbol "ABAX."

How often does Abaxis pay dividends? What is the dividend yield for Abaxis?

Abaxis declared a quarterly dividend on Thursday, January 25th. Shareholders of record on Thursday, March 1st will be paid a dividend of $0.16 per share on Thursday, March 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date is Wednesday, February 28th. View Abaxis' Dividend History.

How will Abaxis' stock buyback program work?

Abaxis declared that its Board of Directors has authorized a stock buyback plan on Wednesday, October 25th 2017, which permits the company to repurchase $21,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.

How were Abaxis' earnings last quarter?

Abaxis Inc (NASDAQ:ABAX) released its quarterly earnings data on Thursday, January, 25th. The medical research company reported $0.31 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.26 by $0.05. The medical research company had revenue of $59.70 million for the quarter, compared to the consensus estimate of $59.37 million. Abaxis had a net margin of 10.51% and a return on equity of 10.09%. The firm's revenue was up 13.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.30 earnings per share. View Abaxis' Earnings History.

When will Abaxis make its next earnings announcement?

Abaxis is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for Abaxis.

Where is Abaxis' stock going? Where will Abaxis' stock price be in 2018?

6 brokers have issued 12-month price objectives for Abaxis' stock. Their forecasts range from $48.00 to $65.00. On average, they anticipate Abaxis' share price to reach $56.63 in the next year. View Analyst Ratings for Abaxis.

Who are some of Abaxis' key competitors?

Who are Abaxis' key executives?

Abaxis' management team includes the folowing people:

  • Clinton H. Severson, Chairman of the Board, Chief Executive Officer (Age 69)
  • Donald Peter Wood, President, Chief Operating Officer (Age 65)
  • Ross Taylor, Chief Financial Officer, Vice President - Finance, Secretary (Age 53)
  • Kenneth P. Aron Ph.D., Chief Technology Officer (Age 64)
  • Craig M. Tockman, Vice President - Animal Health Sales and Marketing for North America (Age 57)
  • Achim Henkel, Managing Director of Abaxis Europe GmbH (Age 59)
  • Vernon Edward Altman, Lead Independent Director (Age 72)
  • Richard J. Bastiani Ph.D., Independent Director (Age 74)
  • Michael D. Casey, Independent Director (Age 71)
  • Henk J. Evenhuis, Independent Director (Age 74)

Who owns Abaxis stock?

Abaxis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Brown Capital Management LLC (12.66%), BlackRock Inc. (12.46%), Copeland Capital Management LLC (1.45%), Bank of New York Mellon Corp (1.41%), Fred Alger Management Inc. (1.34%) and Geode Capital Management LLC (0.92%). Company insiders that own Abaxis stock include Achim Henkel, Clinton Severson, Craig Tockman, Donald Peter Wood, Henk Evenhuis, Kenneth Aron, Prithipal Singh and Richard Bastiani. View Institutional Ownership Trends for Abaxis.

Who sold Abaxis stock? Who is selling Abaxis stock?

Abaxis' stock was sold by a variety of institutional investors in the last quarter, including Brown Capital Management LLC, Millennium Management LLC, Fred Alger Management Inc., Elkfork Partners LLC, Metropolitan Life Insurance Co. NY, Meadow Creek Investment Management LLC, Copeland Capital Management LLC and Deutsche Bank AG. Company insiders that have sold Abaxis company stock in the last year include Achim Henkel, Craig Tockman and Prithipal Singh. View Insider Buying and Selling for Abaxis.

Who bought Abaxis stock? Who is buying Abaxis stock?

Abaxis' stock was acquired by a variety of institutional investors in the last quarter, including Nuance Investments LLC, BlackRock Inc., Renaissance Technologies LLC, Arizona State Retirement System, Schwab Charles Investment Management Inc., Two Sigma Investments LP, MetLife Investment Advisors LLC and Geode Capital Management LLC. View Insider Buying and Selling for Abaxis.

How do I buy Abaxis stock?

Shares of Abaxis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abaxis' stock price today?

One share of Abaxis stock can currently be purchased for approximately $66.95.

How big of a company is Abaxis?

Abaxis has a market capitalization of $1.55 billion and generates $227.22 million in revenue each year. The medical research company earns $32.71 million in net income (profit) each year or $1.08 on an earnings per share basis. Abaxis employs 584 workers across the globe.

How can I contact Abaxis?

Abaxis' mailing address is 3240 WHIPPLE ROAD, UNION CITY CA, 94587. The medical research company can be reached via phone at 510-675-6500 or via email at [email protected]


MarketBeat Community Rating for Abaxis (ABAX)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  277 (Vote Underperform)
Total Votes:  421
MarketBeat's community ratings are surveys of what our community members think about Abaxis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Abaxis (NASDAQ:ABAX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.142.002.00
Ratings Breakdown: 1 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $56.63$49.63$47.63$48.63
Price Target Upside: 11.79% downside20.52% downside3.44% downside3.28% upside

Abaxis (NASDAQ:ABAX) Consensus Price Target History

Price Target History for Abaxis (NASDAQ:ABAX)

Abaxis (NASDAQ:ABAX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018Bank of AmericaBoost Price TargetUnderperform -> Sell$46.00 -> $48.00MediumView Rating Details
1/29/2018Canaccord GenuityReiterated RatingHold$65.00LowView Rating Details
1/26/2018Stifel NicolausBoost Price TargetHold -> Hold$48.00 -> $57.00HighView Rating Details
1/9/2018Raymond James FinancialUpgradeUnderperform -> Market PerformMediumView Rating Details
1/5/2018Northcoast ResearchUpgradeNeutral -> BuyHighView Rating Details
12/1/2017AegisReiterated RatingHoldHighView Rating Details
2/1/2017Seaport Global SecuritiesUpgradeBuyN/AView Rating Details
8/16/2016Credit Suisse GroupReiterated RatingSell$39.00N/AView Rating Details
7/22/2016Feltl & Co.DowngradeHold -> SellN/AView Rating Details
4/1/2016CL KingInitiated CoverageNeutralN/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Abaxis (NASDAQ:ABAX) Earnings History and Estimates Chart

Earnings by Quarter for Abaxis (NASDAQ:ABAX)

Abaxis (NASDAQ ABAX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018$0.31N/AView Earnings Details
1/25/2018Q3 2018$0.26$0.31$59.37 million$59.70 millionViewListenView Earnings Details
10/24/2017Q2 2018$0.27$0.29$60.85 million$58.90 millionViewN/AView Earnings Details
7/27/2017Q1 2018$0.33$0.28$60.37 million$58.26 millionViewN/AView Earnings Details
4/27/2017Q4 2017$0.33$0.33$58.04 million$58.20 millionViewN/AView Earnings Details
1/26/2017Q317$0.31$0.30$54.36 million$52.80 millionViewN/AView Earnings Details
10/25/2016Q217$0.35$0.34$60.69 million$58.60 millionViewListenView Earnings Details
7/21/2016Q117$0.32$0.30$58.70 million$57.70 millionViewListenView Earnings Details
4/28/2016Q416$0.32$0.36$56.62 million$57.00 millionViewListenView Earnings Details
1/28/2016Q316$0.33$0.35$58.52 million$52.90 millionViewListenView Earnings Details
10/27/2015Q216$0.32$0.34$56.20 million$56.00 millionViewListenView Earnings Details
7/23/2015Q116$0.28$0.31$53.75 million$53.10 millionViewListenView Earnings Details
4/30/2015Q415$0.27$0.17$55.62 million$52.00 millionViewN/AView Earnings Details
1/29/2015Q315$0.25$0.26$51.70 million$59.50 millionViewN/AView Earnings Details
10/21/2014Q215$0.23$0.24$50.55 million$53.90 millionViewListenView Earnings Details
7/24/2014Q115$0.19$0.21$46.95 million$47.50 millionViewN/AView Earnings Details
4/24/2014Q414$0.19$0.17$45.74 million$42.04 millionViewN/AView Earnings Details
1/31/2014Q314$0.20$0.14$49.47 million$40.00 millionViewN/AView Earnings Details
10/22/2013Q114$0.21$0.18$48.60 million$45.90 millionViewN/AView Earnings Details
7/25/2013Q1 2014$0.23$0.14$49.13 million$43.20 millionViewListenView Earnings Details
4/25/2013Q4 2013$0.26$0.30$52.47 million$50.00 millionViewListenView Earnings Details
1/31/2013Q3 2013$0.20$0.22$45.75 million$49.80 millionViewListenView Earnings Details
10/23/2012$0.18$0.18ViewN/AView Earnings Details
7/26/2012$0.17$0.13ViewN/AView Earnings Details
4/26/2012$0.16$0.21ViewN/AView Earnings Details
1/26/2012$0.16$0.13ViewN/AView Earnings Details
10/25/2011$0.14$0.15ViewN/AView Earnings Details
7/28/2011$0.16$0.10ViewN/AView Earnings Details
4/28/2011$0.16$0.15ViewN/AView Earnings Details
1/27/2011$0.18$0.17ViewN/AView Earnings Details
10/26/2010Q2 2011$0.17$0.17ViewN/AView Earnings Details
7/29/2010Q1 2011$0.16$0.16ViewN/AView Earnings Details
4/29/2010Q4 2010$0.17$0.12ViewN/AView Earnings Details
1/28/2010Q3 2010$0.17$0.15ViewN/AView Earnings Details
10/27/2009Q2 2010$0.17$0.14ViewN/AView Earnings Details
7/30/2009Q1 2010$0.14$0.17ViewN/AView Earnings Details
4/29/2009Q4 2009$0.17$0.12ViewN/AView Earnings Details
1/29/2009Q3 2009$0.16$0.15ViewN/AView Earnings Details
10/27/2008Q2 2009$0.16$0.15ViewN/AView Earnings Details
7/24/2008Q1 2009$0.16$0.12ViewN/AView Earnings Details
5/1/2008Q4 2008$0.16$0.15ViewN/AView Earnings Details
1/31/2008Q3 2008$0.16$0.14ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Abaxis (NASDAQ:ABAX) Earnings Estimates

2018 EPS Consensus Estimate: $1.33
2019 EPS Consensus Estimate: $1.51
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.33$0.33$0.33
Q2 20181$0.38$0.38$0.38
Q3 20181$0.30$0.30$0.30
Q4 20181$0.32$0.32$0.32
Q1 20191$0.38$0.38$0.38
Q2 20191$0.40$0.40$0.40
Q3 20191$0.32$0.32$0.32
Q4 20191$0.41$0.41$0.41
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Abaxis (NASDAQ:ABAX) Dividend Information

Next Dividend:3/15/2018
Annual Dividend:$0.64
Dividend Yield:0.96%
Payout Ratio:59.26% (Trailing 12 Months of Earnings)
53.33% (Based on This Year's Estimates)
46.04% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Abaxis (NASDAQ:ABAX)

Abaxis (NASDAQ:ABAX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/25/2018quarterly$0.160.00248292985723153%2/28/20183/1/20183/15/2018
10/24/2017quarterly$0.161.28%11/30/201712/1/201712/15/2017
7/27/2017quarterly$0.141.19%8/30/20179/1/20179/15/2017
4/27/2017quarterly$0.141.24%5/30/20176/1/20176/15/2017
1/26/2017quarterly$0.141.13%2/27/20173/1/20173/15/2017
10/28/2016quarterly$0.141.17%11/29/201612/1/201612/15/2016
7/21/2016quarterly$0.121.04%8/30/20169/1/20169/15/2016
4/28/2016quarterly$0.121.06%6/1/20166/3/20166/17/2016
1/28/2016quarterly$0.111.01%3/1/20163/3/20163/17/2016
11/3/2015quarterly$0.110.84%12/1/201512/3/201512/17/2015
7/23/2015quarterly$0.110.9%9/1/20159/3/20159/17/2015
4/30/2015quarterly$0.110.79%6/2/20156/4/20156/18/2015
1/30/2015quarterly$0.100.65%2/27/20153/3/20153/17/2015
10/23/2014quarterly$0.100.82%11/13/201411/17/201412/16/2014
7/24/2014quarterly$0.100.86%8/29/20149/3/20149/17/2014
4/24/2014quarterly$0.105/30/20146/3/20146/17/2014
12/6/2012special$1.0012/13/201212/17/201212/28/2012
(Data available from 1/1/2013 forward)

Insider Trades

Abaxis (NASDAQ ABAX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 99.34%
Insider Trades by Quarter for Abaxis (NASDAQ:ABAX)
Institutional Ownership by Quarter for Abaxis (NASDAQ:ABAX)

Abaxis (NASDAQ ABAX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/31/2018Craig TockmanVPSell1,650$74.33$122,644.5010,866View SEC Filing  
1/31/2018Prithipal SinghDirectorSell2,000$74.63$149,260.0044,000View SEC Filing  
5/26/2017Achim HenkelInsiderSell650$48.87$31,765.5058,950View SEC Filing  
5/8/2017Achim HenkelDirectorSell8,650$47.75$413,037.5068,150View SEC Filing  
2/2/2017Richard BastianiDirectorSell4,000$51.12$204,480.0049,178View SEC Filing  
12/6/2016Clinton SeversonCEOSell15,000$51.35$770,250.00562,300View SEC Filing  
12/2/2016Kenneth AronInsiderSell5,000$51.09$255,450.0092,151View SEC Filing  
9/9/2016Clinton SeversonCEOSell2,000$48.29$96,580.00574,691View SEC Filing  
9/8/2016Prithipal SinghDirectorSell1,000$49.50$49,500.0042,500View SEC Filing  
8/25/2016Prithipal SinghDirectorSell1,500$50.30$75,450.0043,500View SEC Filing  
8/24/2016Donald Peter WoodInsiderSell8,500$50.21$426,785.0052,618View SEC Filing  
6/9/2016Richard BastianiDirectorSell5,000$46.75$233,750.0054,400View SEC Filing  
5/17/2016Achim HenkelDirectorSell5,000$44.43$222,150.0053,609View SEC Filing  
5/9/2016Henk EvenhuisDirectorSell3,000$45.00$135,000.0015,400View SEC Filing  
2/9/2016Vernon E AltmanDirectorBuy303$39.87$12,080.6116,303View SEC Filing  
12/8/2015Craig TockmanVPSell560$54.44$30,486.401,189View SEC Filing  
2/9/2015Prithipal SinghDirectorSell2,500$60.50$151,250.00View SEC Filing  
12/8/2014Kenneth AronCTOSell2,000$56.68$113,360.00View SEC Filing  
11/25/2014Clinton SeversonCEOSell2,286$56.00$128,016.00View SEC Filing  
11/13/2014Clinton SeversonCEOSell10,000$55.00$550,000.00View SEC Filing  
11/5/2014Clinton SeversonCEOSell10,000$54.00$540,000.00View SEC Filing  
11/3/2014Alberto Santa InesCFOSell1,652$53.09$87,704.68View SEC Filing  
11/3/2014Clinton SeversonCEOSell5,000$53.00$265,000.00View SEC Filing  
10/31/2014Clinton SeversonCEOSell10,000$51.50$515,000.00View SEC Filing  
8/12/2014Richard BastianiDirectorSell1,000$45.40$45,400.00View SEC Filing  
7/30/2014Alberto Santa InesCFOSell10,738$47.81$513,383.78View SEC Filing  
7/29/2014Alberto Santa InesCFOSell17,293$48.01$830,236.93View SEC Filing  
6/5/2014Richard BastianiDirectorSell2,000$42.10$84,200.00View SEC Filing  
6/3/2014Richard BastianiDirectorSell4,000$41.88$167,520.00View SEC Filing  
5/22/2014Achim HenkelDirectorSell8,500$41.63$353,855.00View SEC Filing  
5/14/2014Henk EvenhuisDirectorSell4,000$44.06$176,240.0010,400View SEC Filing  
5/1/2014Henk EvenhuisDirectorSell4,500$41.00$184,500.0014,400View SEC Filing  
3/4/2014Vladimir OstoichVPSell9,800$38.53$377,594.00381,987View SEC Filing  
2/24/2014Kenneth AronCTOSell1,000$38.98$38,980.0064,330View SEC Filing  
2/13/2014Donald Peter WoodCOOSell8,864$38.50$341,264.0020,634View SEC Filing  
6/7/2013Clinton SeversonCEOSell10,000$44.50$445,000.00View SEC Filing  
6/7/2013Martin MulroyInsiderSell14,000$44.80$627,200.00View SEC Filing  
5/22/2013Kenneth AronCTOSell4,200$43.28$181,776.00View SEC Filing  
5/7/2013Achim HenkelDirectorSell5,000$44.07$220,350.00View SEC Filing  
3/1/2013Achim HenkelDirectorSell1,000$42.85$42,850.00View SEC Filing  
2/26/2013Martin MulroyInsiderSell12,000$41.84$502,080.00View SEC Filing  
2/5/2013Kenneth AronCTOSell40,000$44.13$1,765,200.00View SEC Filing  
2/4/2013Martin MulroyInsiderSell12,000$43.97$527,640.00View SEC Filing  
11/23/2012Richard BastianiDirectorSell5,000$36.60$183,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Abaxis (NASDAQ ABAX) News Headlines

Source:
DateHeadline
Abaxis, Inc. to Present at the Bank of America Merrill Lynch Animal Health Summit and the Raymond James 39th Annual Institutional Investors ConferenceAbaxis, Inc. to Present at the Bank of America Merrill Lynch Animal Health Summit and the Raymond James 39th Annual Institutional Investors Conference
finance.yahoo.com - February 22 at 9:14 AM
Abaxis Inc (ABAX) Given Consensus Rating of "Hold" by AnalystsAbaxis Inc (ABAX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 20 at 9:34 PM
Critical Comparison: Abaxis (ABAX) & Invivo Therapeutics (NVIV)Critical Comparison: Abaxis (ABAX) & Invivo Therapeutics (NVIV)
www.americanbankingnews.com - February 19 at 1:20 PM
Cytosorbents (CTSO) and Abaxis (ABAX) Critical AnalysisCytosorbents (CTSO) and Abaxis (ABAX) Critical Analysis
www.americanbankingnews.com - February 15 at 3:18 AM
Abaxis Inc (ABAX) Expected to Announce Quarterly Sales of $66.23 MillionAbaxis Inc (ABAX) Expected to Announce Quarterly Sales of $66.23 Million
www.americanbankingnews.com - February 10 at 6:34 AM
Abaxis (ABAX) PT Raised to $48.00 at Bank of AmericaAbaxis (ABAX) PT Raised to $48.00 at Bank of America
www.americanbankingnews.com - February 8 at 1:30 PM
Abaxis (ABAX) & Neovasc Inc (US) (NVCN) Critical AnalysisAbaxis (ABAX) & Neovasc Inc (US) (NVCN) Critical Analysis
www.americanbankingnews.com - February 7 at 3:08 AM
Free Post Earnings Research Report: Abaxis’s Revenues Advanced 13.07%; Adjusted EPS Grew 3.33%Free Post Earnings Research Report: Abaxis’s Revenues Advanced 13.07%; Adjusted EPS Grew 3.33%
finance.yahoo.com - February 5 at 9:11 AM
Form 4 ABAXIS INC For: Jan 31 Filed by: TOCKMAN CRAIGForm 4 ABAXIS INC For: Jan 31 Filed by: TOCKMAN CRAIG
www.streetinsider.com - February 3 at 9:05 AM
Insider Selling: Abaxis Inc (ABAX) Director Sells 2,000 Shares of StockInsider Selling: Abaxis Inc (ABAX) Director Sells 2,000 Shares of Stock
www.americanbankingnews.com - February 1 at 9:30 PM
Insider Selling: Abaxis Inc (ABAX) VP Sells 1,650 Shares of StockInsider Selling: Abaxis Inc (ABAX) VP Sells 1,650 Shares of Stock
www.americanbankingnews.com - February 1 at 9:30 PM
Abaxis Inc Forecasted to Post Q3 2019 Earnings of $0.32 Per Share (ABAX)Abaxis Inc Forecasted to Post Q3 2019 Earnings of $0.32 Per Share (ABAX)
www.americanbankingnews.com - February 1 at 2:50 PM
Abaxis (ABAX) Rating Lowered to Hold at Zacks Investment ResearchAbaxis (ABAX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 31 at 3:22 PM
FY2018 EPS Estimates for Abaxis Inc Increased by Northcoast Research (ABAX)FY2018 EPS Estimates for Abaxis Inc Increased by Northcoast Research (ABAX)
www.americanbankingnews.com - January 31 at 12:51 PM
Abaxis (ABAX) Upgraded to Buy by Zacks Investment ResearchAbaxis (ABAX) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - January 30 at 12:30 PM
Abaxis (ABAX) at a 52-Week High: What's Driving the Stock?Abaxis (ABAX) at a 52-Week High: What's Driving the Stock?
finance.yahoo.com - January 30 at 9:37 AM
Abaxis (ABAX) Receives Hold Rating from Canaccord GenuityAbaxis (ABAX) Receives Hold Rating from Canaccord Genuity
www.americanbankingnews.com - January 29 at 1:46 PM
Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q3Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q3
www.zacks.com - January 29 at 9:19 AM
Fulgent Genetics (FLGT) & Abaxis (ABAX) Critical ComparisonFulgent Genetics (FLGT) & Abaxis (ABAX) Critical Comparison
www.americanbankingnews.com - January 27 at 9:14 PM
Abaxis Inc. (ABAX) Has Risen To A New High Following Q3 ReportAbaxis Inc. (ABAX) Has Risen To A New High Following Q3 Report
www.nasdaq.com - January 27 at 9:37 AM
Stifel Nicolaus Increases Abaxis (ABAX) Price Target to $57.00Stifel Nicolaus Increases Abaxis (ABAX) Price Target to $57.00
www.americanbankingnews.com - January 26 at 11:18 PM
Abaxis Inc (ABAX) Given Consensus Rating of "Hold" by BrokeragesAbaxis Inc (ABAX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 26 at 9:24 PM
Abaxis Inc. Q3 Income DeclinesAbaxis Inc. Q3 Income Declines
www.nasdaq.com - January 26 at 9:19 AM
Abaxis beats 3Q profit forecastsAbaxis beats 3Q profit forecasts
finance.yahoo.com - January 26 at 9:19 AM
Abaxis (ABAX) Posts Quarterly  Earnings Results, Beats Expectations By $0.05 EPSAbaxis (ABAX) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - January 25 at 9:16 PM
Abaxis Inc Announces Quarterly Dividend of $0.16 (ABAX)Abaxis Inc Announces Quarterly Dividend of $0.16 (ABAX)
www.americanbankingnews.com - January 25 at 5:40 PM
Earnings Preview For AbaxisEarnings Preview For Abaxis
finance.yahoo.com - January 25 at 4:22 PM
Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2018 and Declares Quarterly Cash DividendAbaxis Reports Financial Performance for the Third Quarter of Fiscal 2018 and Declares Quarterly Cash Dividend
finance.yahoo.com - January 25 at 4:22 PM
With A Recent ROE Of 10.31%, Can Abaxis Inc (NASDAQ:ABAX) Catch Up To Its Industry?With A Recent ROE Of 10.31%, Can Abaxis Inc (NASDAQ:ABAX) Catch Up To Its Industry?
finance.yahoo.com - January 25 at 4:22 PM
BRIEF-Abaxis Announces USDA Approval Of New VetScan FLEX4 Rapid TestBRIEF-Abaxis Announces USDA Approval Of New VetScan FLEX4 Rapid Test
www.reuters.com - January 23 at 8:13 AM
Abaxis, Inc. Announces USDA Approval of New VetScan FLEX4 Rapid TestAbaxis, Inc. Announces USDA Approval of New VetScan FLEX4 Rapid Test
finance.yahoo.com - January 22 at 5:54 PM
Financial Analysis: Fulgent Genetics (FLGT) versus Abaxis (ABAX)Financial Analysis: Fulgent Genetics (FLGT) versus Abaxis (ABAX)
www.americanbankingnews.com - January 20 at 11:30 PM
Abaxis (ABAX) Cut to "Sell" at BidaskClubAbaxis (ABAX) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - January 20 at 12:33 PM
Abaxis To Report Third Quarter Fiscal Year 2018 Financial Results On Thursday ...Abaxis To Report Third Quarter Fiscal Year 2018 Financial Results On Thursday ...
www.prnewswire.com - January 18 at 7:14 PM
Abaxis To Report Third Quarter Fiscal Year 2018 Financial Results On Thursday, January 25, 2018Abaxis To Report Third Quarter Fiscal Year 2018 Financial Results On Thursday, January 25, 2018
finance.yahoo.com - January 17 at 11:06 AM
Abaxis (ABAX) Set to Announce Quarterly Earnings on WednesdayAbaxis (ABAX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - January 17 at 1:28 AM
Abaxis Inc (ABAX) to Post Q3 2018 Earnings of $0.30 Per Share, Northcoast Research ForecastsAbaxis Inc (ABAX) to Post Q3 2018 Earnings of $0.30 Per Share, Northcoast Research Forecasts
www.americanbankingnews.com - January 11 at 2:02 PM
Abaxis Inc. (ABAX) PT Raised to $42 at Credit Suisse on 3Q Pre-Announcement Ahead of Estimates, ConsensusAbaxis Inc. (ABAX) PT Raised to $42 at Credit Suisse on 3Q Pre-Announcement Ahead of Estimates, Consensus
www.streetinsider.com - January 11 at 11:42 AM
Abaxis (ABAX) Preliminary Results for Q3 Cheer InvestorsAbaxis' (ABAX) Preliminary Results for Q3 Cheer Investors
finance.yahoo.com - January 11 at 11:42 AM
Abaxis' (ABAX) Preliminary Results for Q3 Cheer InvestorsAbaxis' (ABAX) Preliminary Results for Q3 Cheer Investors
finance.yahoo.com - January 11 at 11:42 AM
FY2018 Earnings Forecast for Abaxis Inc (ABAX) Issued By Northcoast ResearchFY2018 Earnings Forecast for Abaxis Inc (ABAX) Issued By Northcoast Research
www.americanbankingnews.com - January 10 at 5:10 PM
Abaxis Inc. (ABAX) Has Jumped To A New High On Q3 ForecastAbaxis Inc. (ABAX) Has Jumped To A New High On Q3 Forecast
www.nasdaq.com - January 10 at 11:13 AM
Abaxis Reports Preliminary Financial Performance for the Third Quarter of Fiscal 2018Abaxis Reports Preliminary Financial Performance for the Third Quarter of Fiscal 2018
finance.yahoo.com - January 9 at 10:59 AM
Zeltiq Aesthetics (ZLTQ) and Abaxis (ABAX) Head to Head ComparisonZeltiq Aesthetics (ZLTQ) and Abaxis (ABAX) Head to Head Comparison
www.americanbankingnews.com - January 9 at 5:10 AM
Abaxis (ABAX) Rating Lowered to Sell at Zacks Investment ResearchAbaxis (ABAX) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 8 at 3:58 PM
Northcoast Research Weighs in on Abaxis Incs Q3 2018 Earnings (ABAX)Northcoast Research Weighs in on Abaxis Inc's Q3 2018 Earnings (ABAX)
www.americanbankingnews.com - January 8 at 7:12 AM
$56.71 Million in Sales Expected for Abaxis Inc (ABAX) This Quarter$56.71 Million in Sales Expected for Abaxis Inc (ABAX) This Quarter
www.americanbankingnews.com - January 7 at 8:56 AM
Abaxis (ABAX) Upgraded at Northcoast ResearchAbaxis (ABAX) Upgraded at Northcoast Research
www.americanbankingnews.com - January 5 at 5:22 PM
Abaxis Inc (ABAX) Receives Average Recommendation of "Hold" from BrokeragesAbaxis Inc (ABAX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 1 at 9:40 PM
Abaxis, Inc. (ABAX)Abaxis, Inc. (ABAX)
finance.yahoo.com - December 31 at 10:37 AM

SEC Filings

Abaxis (NASDAQ:ABAX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Abaxis (NASDAQ:ABAX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Abaxis (NASDAQ ABAX) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.